UROLOGIX TARGIS MICROWAVE BPH THERAPY DEVICE TO LIST AT $150,000, FIRM SAYS; FDA APPROVAL CLEARS WAY FOR LAUNCH OF COMPETITION TO EDAP'S PROSTATRON
This article was originally published in The Gray Sheet
Urologix is heating up competition in the benign prostatic hyperplasia microwave therapy market with the U.S. launch of its Targis system, which is slated for the fourth quarter of 1997. Urologix is the second company, after Edap Technomed, to gain approval for a microwave-based BPH therapy system.
You may also be interested in...
ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.